OXULAR LTD

Oxular is a clinical-stage retinal therapeutics company developing technology to transform the treatment of retinal diseases including diabetic macular edema (DME) and macular degeneration.

DME is a serious retinal disease that affects 24 million people globally and is the leading cause of blindness in young adults in developed countries.

It is also developing programmes for conditions such as ocular cancers and the delivery of gene therapies.

A key challenge facing patients with DME precise molecular analyses, launched its highly anticipated IPO on the London Stock Exchange, pricing the company at £3.4 billion. is the need for frequent clinic visits for repeated treatment injections.

The company, which started to sell its first commercial device, the MinION portable DNA/RNA sequencer in 2015, is looking to bring DNA sequencing out of the laboratory and into the consumer market.

To address this, OXU-001, an innovative, sustained-release formulation of dexamethasone, provides up to 12 months’ treatment effects following a single administration.

Oxular’s products include Oxuspheres, a drug-containing biodegradable polymer system, designed as an adjustable, sustained release formulation, and Oxulumi, a semi-automated ocular administration device using an advantageous route of administration to deliver therapeutics for the treatment of retinal diseases.

In March 2021, the Oxford-based biotech secured £27 million financing led by Forbion Capital Partners with support from the company’s existing leading investors.

The investment will fund Phase 2 human clinical studies.